Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

53 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A randomized controlled trial evaluating the efficacy and safety of intermittent 3-, 4-, and 5-day cycles of intravenous recombinant human interleukin-2 combined with antiretroviral therapy (ART) versus ART alone in HIV-seropositive patients with 100-300 CD4+ T cells.
de Boer AW, Markowitz N, Lane HC, Saravolatz LD, Koletar SL, Donabedian H, Yoshizawa C, Duliege AM, Fyfe G, Mitsuyasu RT. de Boer AW, et al. Among authors: duliege am. Clin Immunol. 2003 Mar;106(3):188-96. doi: 10.1016/s1521-6616(02)00038-4. Clin Immunol. 2003. PMID: 12706405 Clinical Trial.
Immunologic and virologic effects of subcutaneous interleukin 2 in combination with antiretroviral therapy: A randomized controlled trial.
Davey RT Jr, Murphy RL, Graziano FM, Boswell SL, Pavia AT, Cancio M, Nadler JP, Chaitt DG, Dewar RL, Sahner DK, Duliege AM, Capra WB, Leong WP, Giedlin MA, Lane HC, Kahn JO. Davey RT Jr, et al. Among authors: duliege am. JAMA. 2000 Jul 12;284(2):183-9. doi: 10.1001/jama.284.2.183. JAMA. 2000. PMID: 10889591 Clinical Trial.
The virologic, immunologic, and clinical effects of interleukin 2 with potent antiretroviral therapy in patients with moderately advanced human immunodeficiency virus infection: a randomized controlled clinical trial--AIDS Clinical Trials Group 328.
Mitsuyasu R, Gelman R, Cherng DW, Landay A, Fahey J, Reichman R, Erice A, Bucy RP, Kilby JM, Lederman MM, Hamilton CD, Lertora J, White BL, Tebas P, Duliege AM, Pollard RB; AIDS Clinical Trials Group 328 Study Team. Mitsuyasu R, et al. Among authors: duliege am. Arch Intern Med. 2007 Mar 26;167(6):597-605. doi: 10.1001/archinte.167.6.597. Arch Intern Med. 2007. PMID: 17389292 Clinical Trial.
Safety, pharmacokinetics, and antiviral response of CD4-immunoglobulin G by intravenous bolus in AIDS and AIDS-related complex.
Collier AC, Coombs RW, Katzenstein D, Holodniy M, Gibson J, Mordenti J, Izu AE, Duliege AM, Ammann AJ, Merigan T, et al. Collier AC, et al. Among authors: duliege am. J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Oct 1;10(2):150-6. doi: 10.1097/00042560-199510020-00006. J Acquir Immune Defic Syndr Hum Retrovirol. 1995. PMID: 7552478 Clinical Trial.
CD4 immunoadhesins in anti-HIV therapy: new developments.
Chamow SM, Duliege AM, Ammann A, Kahn JO, Allen JD, Eichberg JW, Byrn RA, Capon DJ, Ward RH, Ashkenazi A. Chamow SM, et al. Among authors: duliege am. Int J Cancer Suppl. 1992;7:69-72. Int J Cancer Suppl. 1992. PMID: 1428410 Review.
Phase I study of continuous-infusion soluble CD4 as a single agent and in combination with oral dideoxyinosine therapy in children with symptomatic human immunodeficiency virus infection.
Husson RN, Chung Y, Mordenti J, Butler KM, Chen S, Duliege AM, Brouwers P, Jarosinski P, Mueller BU, Ammann A, et al. Husson RN, et al. Among authors: duliege am. J Pediatr. 1992 Oct;121(4):627-33. doi: 10.1016/s0022-3476(05)81161-8. J Pediatr. 1992. PMID: 1357124 Clinical Trial.
Prime-boost immunization strategies against HIV.
Barnett SW, Klinger JM, Doe B, Walker CM, Hansen L, Duliège AM, Sinangil FM. Barnett SW, et al. Among authors: duliege am. AIDS Res Hum Retroviruses. 1998 Oct;14 Suppl 3:S299-309. AIDS Res Hum Retroviruses. 1998. PMID: 9814958 Review. No abstract available.
Safety of 2 recombinant human immunodeficiency virus type 1 (HIV-1) envelope vaccines in neonates born to HIV-1-infected women.
Cunningham CK, Wara DW, Kang M, Fenton T, Hawkins E, McNamara J, Mofenson L, Duliege AM, Francis D, McFarland EJ, Borkowsky W; Pediatric AIDS Clinical Trials Group 230 Collaborators. Cunningham CK, et al. Among authors: duliege am. Clin Infect Dis. 2001 Mar 1;32(5):801-7. doi: 10.1086/319215. Epub 2001 Feb 28. Clin Infect Dis. 2001. PMID: 11229849 Clinical Trial.
Transport of recombinant human CD4-immunoglobulin G across the human placenta: pharmacokinetics and safety in six mother-infant pairs in AIDS clinical trial group protocol 146.
Shearer WT, Duliege AM, Kline MW, Hammill H, Minkoff H, Ammann AJ, Chen S, Izu A, Mordenti J. Shearer WT, et al. Among authors: duliege am. Clin Diagn Lab Immunol. 1995 May;2(3):281-5. doi: 10.1128/cdli.2.3.281-285.1995. Clin Diagn Lab Immunol. 1995. PMID: 7664172 Free PMC article. Clinical Trial.
53 results